Table 4.
Treatment results of patients according to AML-BFM 2004 Interim protocol compared to earlier studies in Poland
| Parameters | AML-PPLLSG 83 | AML-PPLLSG 94 | AML-PPLLSG 98 | AML-BFM 2004 INTERIM |
|---|---|---|---|---|
| 1983–1994 | 1994–1997 | 1998–2004 | 2005–2011 | |
| [3] | [3] | [9] | ||
| N (%) | N (%) | N (%)e | N (%) | |
| No. of patients | 208 | 83 | 195 | 237 |
| Early death | 46 (22.1) | 12 (15.1) | 16 (8.0) | 11, including in M3-3 and M5-4 (4.2) |
| Blasts day 15 ³ 5 %a | ND | 34/72 (47.2 | 47/182 (25.6 | 56/216 (25.9) |
| Nonresponders | 13 (5.7) | 15 (18.0) | 20 (10.3) | 19 (8.5) |
| CR achieved | 150 (71.4) | 56 (67.5) | 159 (82.0) | 207 (87.3) |
| Death in CCR (including death after SCT in first CR)b | 20 (0) (9.6) | 9 (3) (10.8) | 18 (5) (9.2) | 14 (3) (5.9) |
| Relapse (cumulative incidence) | ND | ND | ND | 36.4 ± 3.7 |
| Secondary malignancies | ND | ND | ND | 0 (0) |
|
Total group pSurvival (5 years) |
33 ± 3 | 38 ± 5 | 53 ± 5 | 63.1 ± 3.3 |
|
Total group pEFS (5 years) |
32 ± 3 | 36 ± 5 | 47 ± 5 | 51.8 ± 3.4 |
| SR pEFS (5 years) | NA | 37 ± 8 | 62 ± 7 | 55.0 ± 6.6 |
| HR pEFS (5 years) | NA | 41 ± 8 | 33 ± 7 | 50.6 ± 4.0 |
AML-BFM acute myeloid leukemia-Berlin–Frankfurt–Munster, AML-PPLLSG acute myeloid leukemia-Polish pediatric leukemia/lymphoma study group, CR complete remission, CCR continous complete remission, HSCT hematopoietic stem cell transplantation, NA not applicable, ND non definedaPercentage is given for patients with data (n/total)bThe values in second parenthesis denotes percentage